Volume 34, Issue 1, March 2023

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(1):91-6
Leflunomide Induced Atypical DRESS: A Case Report and Literature Review
Authors Information
1Clinical Pharmacist-AIG Hospitals, India
2Clinical Pharmacist intern, Department of Pharmacy Practice, G. Pulla Reddy College of Pharmacy, India
3Consultant Rheumatologist-AIG Hospitals, India

Drug rash with eosinophilia and systemic symptoms syndrome (DRESS syndrome) is a potentially life-threatening, drug-induced, multi-organ system reaction, the most frequently involved organ is liver, followed by the kidneys and lungs.1 Early detection and diagnosis followed by withdrawal of the offending agent is vital to minimise the associated morbidity and mortality. A detailed drug history is vital to identify the causative drugs. Although Spanish guidelines were developed by a panel of allergy specialists from the Drug Allergy Committee of the Spanish Society of Allergy and Clinical Immunology (SEAIC) and are available in literature from 2020, many clinicians are still unaware about the management of this syndrome. Framing national guidelines for the early diagnosis and Pharmaco-therapeutic management of DRESS will help the healthcare professionals to save the patients from unintended vulnerability. Leflunomide, a drug widely used in rheumatology and orthopaedics must be used with caution since it has the potential to cause DRESS syndrome. We report a case of a lady aged 32 years, presented to our hospital with a history of leflunomide intake and symptoms of DRESS.

Cite this article as: Fatima M, Azimi SS, Ashwini S, Radhakrishna MH. Leflunomide Induced Atypical DRESS: A Case Report and Literature Review. Mediterr J Rheumatol 2023;34(1):91-6.

Article Submitted: 15 Jul 2022; Article Accepted: 12 Aug 2022; Available Online: 31 Mar 2023



This work is licensed under a Creative Commons Attribution 4.0 International License.

©2023 The Author(s).